Henry Ji was named Chief Executive Officer of Semnur Pharmaceuticals, Inc., succeeding Jaisim Shah. As of November 14, 2026, Semnur Pharmaceuticals, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 17, 2026, naming 2 appointments and 1 departure (Form 8-K, March 17, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Semnur Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Jaisim Shah · Role: Chief Executive Officer · Effective: 2026-03-13 · 8-K, 2026-03-17
- · In / out: In · Person: Henry Ji · Role: Chief Executive Officer · 8-K, 2026-03-17
- · In / out: In · Person: Stephen Ma · Role: Chief Operating Officer · Effective: 2026-03-17 · 8-K, 2026-03-17
Semnur Pharmaceuticals, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-17. It names 3 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Semnur Pharmaceuticals, Inc. files it.
Also on the record for Semnur Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 26, 2026 | Stake report, Schedule 13D/A, by Scilex Holding Company | 78.85% of the class | 5%+ stakes | Source |
| October 14, 2025 | Stake report, Schedule 13D/A, by Scilex Holding Company | 82.07% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Meteora Capital, LLC | — | 5%+ stakes | Source |
| August 12, 2025 | Stake report, Schedule 13G/A, by TD SECURITIES (USA) LLC | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Semnur Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Semnur Pharmaceuticals, Inc. and the records around it.
Semnur Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Jun 2026
Companies that share a holder
- Scilex Holding Company also filed stake reports on 2 other companies: DATAVAULT AI INC. (Aug 2026), Semnur Pharmaceuticals, Inc. (Sep 2025)
- TD SECURITIES (USA) LLC also filed stake reports on 33 other companies: Amanat Acquisition Corp. (Nov 2026), Black Spade Acquisition III Co (Nov 2026), Blue Acquisition Corp (Nov 2026)
- Meteora Capital, LLC also filed stake reports on 80 other companies: Dynamix Corp (Nov 2026), Investcorp Europe Acquisition Corp I (Oct 2026), 1RT Acquisition Corp. (Aug 2026)
Watch Semnur Pharmaceuticals, Inc.
Get an email when Semnur Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Semnur Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Semnur Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Semnur Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-17 | Out | Chief Executive Officer | 2026-03-13 | 8-K, 2026-03-17 | |
| 2026-03-17 | In | Chief Executive Officer | 8-K, 2026-03-17 | ||
| 2026-03-17 | In | Chief Operating Officer | 2026-03-17 | 8-K, 2026-03-17 |
Why did they leave? What the filings say
For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Jaisim Shah, Chief Executive Officer (filed 2026-03-17):
Mr. Shah's departure is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Who leads Semnur Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Operating Officer: Stephen Ma, appointed, effective 2026-03-17 (filed 2026-03-17).
- Chief Executive Officer: Henry Ji, appointed (filed 2026-03-17).
New leaders reset buying decisions — get the Full Report on Semnur Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Semnur Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Semnur Pharmaceuticals, Inc.Every change, in the filing's words
Departing: Jaisim Shah, Chief Executive Officer, effective 2026-03-13
Departure of Chief Executive Officer and President; Decrease in Size of Board On March 13, 2026, Jaisim Shah, Chief Executive Officer and President of Semnur Pharmaceuticals, Inc. (the "Company"), notified the Company's board of directors (the "Board") that he is retiring and thus resigning from his positions as Chief Executive Officer and President, and as a director of the Company, and will separate from employment effective as of March 13, 2026 (the "Effective Time").
Appointed: Henry Ji, Chief Executive Officer
Appointment of Chief Executive Officer and President In connection with Mr. Shah's departure, the Board appointed Henry Ji, Ph.D., age 61, as the Company's Chief Executive Officer and President effective as of the Effective Time.
Appointed: Stephen Ma, Chief Operating Officer, effective 2026-03-17
Appointment of Chief Operating Officer In connection with Mr. Shah's departure, the Board also appointed Stephen Ma, age 53, as the Company's Chief Operating Officer, with such appointment effective as of March 17, 2026.
- As a result of Mr. Shah's resignation, the Board has decreased the size of the Board from six directors to five directors as of immediately following the Effective Time.
- In connection with Mr. Shah's departure, the Company and Mr. Shah have entered into a separation agreement, effective as of March 13, 2026 (the "Separation Agreement"), pursuant to which Mr. Shah will receive six months of continued payment of his base salary (at a rate of $1,250,000 per year) and will be given a 90-day extension of the post-termination exercise period under the applicable equity plan to exercise any of his vested stock options pursuant to the award agreements for such options.
- Also, pursuant to the Separation Agreement, Mr. Shah's prior employment agreement dated September 22, 2025 was terminated.
- The Separation Agreement also includes a standard general release of all claims.
- Dr. Ji has served as the Company's Executive Chairperson and a member of the Board since September 2025 and previously served as Semnur's Treasurer and Secretary and a board member since its inception in 2013.
- Dr. Ji has served as Executive Chairperson and a board member of Scilex Holding Company (Nasdaq: SCLX) ("Scilex") since September 2023, as Scilex's President and Chief Executive Officer since August 2025, and previously served as Scilex's Executive Chairperson and board member from March 2019 to August 2023.
Tools for this story
Each opens in a new tab, filled in for Semnur Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
